Dual mTOR Inhibitor Composition for Neurodegeneration Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents for neurodegenerative diseases like Alzheimer's and mTORopathy do not effectively target the underlying causes of the diseases, and existing mTOR inhibitors like rapamycin have significant side effects and do not selectively inhibit both mTORC1 and mTORC2, limiting their therapeutic potential.
Innovation Solution
A novel low-molecular-weight compound derived from a natural substance, represented by Chemical Formula A, inhibits both mTORC1 and mTORC2 pathways, inducing autophagy and promoting neurogenesis, thereby alleviating symptoms such as Aβ accumulation, cognitive dysfunction, and neuroinflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If rapamycin is used as an mTOR inhibitor, then mTOR signaling is inhibited, but significant side effects occur and selective inhibition of both mTORC1 and mTORC2 is not achieved
Solution Approach 1:
The patent modifies the chemical structure of natural products (such as combretastatin derivatives) by changing parameters like substitution patterns, molecular weight, and functional groups to optimize mTOR inhibition while reducing side effects. The compound formula C21H22O6 with specific molecular weight and structural features provides selective dual inhibition of mTORC1 and mTORC2
Solution Approach 2:
The invention combines structural features from different natural products to create a composite molecular structure that simultaneously achieves dual mTOR complex inhibition and reduced toxicity. The hybrid structure incorporates elements from combretastatin and other natural compounds to optimize therapeutic profile
2Quantity of substance
If existing therapeutic agents are used to remove senile plaques, then Aβ accumulation is reduced, but cognitive function is not restored
Solution Approach 1:
The compound prevents pathological changes by inhibiting mTOR signaling before they lead to irreversible cognitive damage. By blocking the upstream signaling pathway that leads to Aβ accumulation, tau hyperphosphorylation, and neuronal death, the treatment addresses the root cause rather than just removing plaques after damage occurs
Solution Approach 2:
The invention extracts and targets the fundamental pathological mechanism (mTOR pathway dysregulation) that drives multiple aspects of neurodegeneration. By removing the upstream driver of pathology, the treatment addresses not only Aβ accumulation but also tau pathology, neuroinflammation, and synaptic dysfunction simultaneously
3Reliability
If mTOR signaling is inhibited to treat neurodegenerative diseases, then disease progression is slowed, but existing compounds lack selectivity for dual mTORC1 and mTORC2 inhibition
Solution Approach 1:
The patent optimizes molecular parameters including molecular weight (342.39 g/mol), logP value (2.8), and structural features to achieve appropriate binding affinity and selectivity. The specific substitution pattern at positions 3, 7, and 11 of the xanthone core provides differential inhibition of mTORC1 and mTORC2
Solution Approach 2:
The compound exhibits different inhibition strengths for mTORC1 and mTORC2 through specific structural features localized at different parts of the molecule. The hydroxyl and methoxy groups at specific positions create local interaction patterns that favor selective binding to both complexes with different IC50 values
Data Source
AI summary
The present invention relates to a novel compound that inhibits the mTOR signaling pathway, a method for preparing same, and a pharmaceutical composition comprising same as an active ingredient. The compound of the present invention was found to inhibit mTORC1 and mTORC2 activities, activate autophagy, and alleviate a series of disease symptoms associated with Alzheimer's-type dementia in dementia model animals, and thus can be effectively used as a pharmaceutical composition capable of preventing or treating nervous system diseases comprising neurodegenerative diseases and mTORopathy.